<DOC>
	<DOCNO>NCT00404989</DOCNO>
	<brief_summary>The purpose Antiretroviral Pregnancy Registry ( Registry ) detect major teratogenic effect involve Registry drug administer pregnant woman . Registration voluntary confidential information obtain health care provider . A Registry-assigned identifier allow follow-up capability . Information subject provide Registry prospectively ( prior outcome pregnancy know ) health care provider , follow-up obtain health care provider outcome determine . Providers strongly urge enroll patient early pregnancy possible maximize validity data . In addition , Registry interest assemble group provider willing make commitment report site 's antiretroviral pregnancy exposure Registry , thereby assure case consider prospective . Providers encourage contact Registry information group . The Registry inform analysis data , example , retrospective report clinical study . Given increase number medication aggressive approach therapy , HIV-infected woman may treat pregnancy become pregnant treatment . The paucity data use infant outcomes antiretroviral therapy pregnancy make Registry essential component ongoing program epidemiologic study safety therapy . Each year Registry enrol approximately 1300 pregnant woman US expose antiretroviral drug . This number represent approximately 15 % 8,700 HIV positive woman give birth live infant annually US .</brief_summary>
	<brief_title>Antiretroviral Pregnancy Registry ( APR ) : Multi-sponsor Registry Detect Any Major Teratogenic Effect Involving Any Registry Drugs When Administered Pregnant Women .</brief_title>
	<detailed_description>The following antiretroviral drug follow Antiretroviral Pregnancy Registry ( APR : Registry ) detect major teratogenic effect administer pregnant woman : abacavir ( ZIAGEN® , ABC ) , abacavir/lamivudine ( EPZICOM® , EPZ ) , abacavir/lamivudine/zidovudine ( TRIZIVIR® , TZV ) , adefovir dipivoxil ( HEPSERA® , ADV ) , amprenavir ( AGENERASE® , APV ) , atazanavir ( REYATAZ® , ATV ) , darunavir ( PREZISTA® , DRV ) , delavirdine mesylate ( RESCRIPTOR® , DLV ) , didanosine ( VIDEX® , VIDEX® EC , ddI ) , dolutegravir ( TIVICAY® , DTG ) , efavirenz ( SUSTIVA® , STOCRIN® , EFV ) , efavirenz/emtricitabine/ tenofovir DF ( ATRIPLA® ATR ) , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( GENVOYA® , GEN ) , elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate ( STRIBILD® , STB ) , emtricitabine ( EMTRIVA® , FTC ) , enfuvirtide ( FUZEON® , T-20 ) , entecavir ( BARACLUDE® , ETV ) , etravirine ( INTELENCE® , ETR ) , fosamprenavir calcium ( LEXIVA® , FOS ) , indinavir ( CRIXIVAN® , IDV ) , lamivudine ( EPIVIR® , 3TC ) , lamivudine/raltegravir ( DUTREBIS™ , DUT ) , lamivudine/zidovudine ( COMBIVIR® , ZDV+3TC ) , lopinavir/ritonavir ( KALETRA® , ALUVIA® , LPV/r ) , maraviroc ( SELZENTRY® , CELSENTRI® , MVC ) , nelfinavir ( VIRACEPT® , NFV ) , nevirapine ( VIRAMUNE® , VIRAMUNE® XR™ , NVP ) , raltegravir ( ISENTRESS® , RAL ) , rilpivirine ( EDURANT® , RPV ) , rilpivirine/emtricitabine/tenofovir DF ( COMPLERA® , CPA ; EVIPLERA® , EPA ) , ritonavir ( NORVIR® , RTV ) , saquinavir ( FORTOVASE® , SQV-SGC ) , saquinavir mesylate ( INVIRASE® , SQV-HGC ) , stavudine ( ZERIT® , d4T ) , telbivudine ( SEBIVO® , TYZEKA® , LdT ) , tenofovir DF ( VIREAD® , TDF ) , tenofovir DF/emtricitabine ( TRUVADA® , TVD ) , tipranavir ( APTIVUS® , TPV ) , zalcitabine ( HIVID® , ddC ) , zidovudine ( RETROVIR® , ZDV ) . Zidovudine indicate use second third trimester pregnancy reduce risk maternal-fetal HIV transmission . There also several complete ongoing study maternal-fetal transmission therapy . However , safety prenatal zidovudine antiretroviral therapy exposure fetus establish .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Eligibility Ages Eligible Study : Women childbearing age Country origin report Documentation registry drug take pregnancy Sufficient information determine pregnancy prospectively retrospectively registered Date pregnancy register Source report ( patient health care provider ) Whether pregnancy outcome already know delivery still pending Timing prenatal exposure registry medication ( broad trimester ) Sufficient patient identifier relevant reporter allow followup Was patient involve study time prenatal exposure Full reporter contact information ( name , address , etc . ) Females expose registry medication pregnancy Male patient</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>HBV</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Registry</keyword>
</DOC>